1P-LSD

Human pharmacokinetic studies in two volunteers demonstrated that oral 1P-LSD is efficiently converted to LSD with near 100% bioavailability, producing subjective effects comparable to LSD with a terminal elimination half-life of approximately 6.4 hours (PMID 32415750). Animal studies confirm 5-HT2A-mediated head-twitch response, with 1P-LSD showing approximately 38% of LSD's potency by molar dose, consistent with prodrug conversion (PMID 26456305, 31756337). However, human data is limited to a single two-subject study, and the full toxicological profile remains largely unexplored. In silico predictions suggest potential hematotoxicity (76% probability) and moderate acute toxicity, though these findings require empirical validation (PMID 41915184). Long-term safety data is absent.